Eli Lilly and Company (LLY)vsThird Harmonic Bio Inc. (THRD)
LLY
Eli Lilly and Company
$1,155.27
-4.52%
HEALTHCARE · Cap: $1.02T
THRD
Third Harmonic Bio Inc.
$5.38
0.00%
HEALTHCARE · Cap: $242.79M
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
THRD
Avoid32
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 33.1x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : THRD
The strongest argument for THRD centers on Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.
Bear Case : THRD
The primary concerns for THRD are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while THRD is a value play — different risk/reward profiles.
THRD carries more volatility with a beta of 2.13 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 32/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Third Harmonic Bio Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Third Harmonic Bio Inc. is an innovative biotechnology company dedicated to advancing breakthrough therapies for severe immunological and inflammatory disorders. Utilizing its proprietary genetic engineering platform, the firm is developing a robust pipeline of drug candidates designed to address significant unmet medical needs within the biopharmaceutical sector. With a strong emphasis on scientific rigor and patient-centric solutions, Third Harmonic Bio is strategically positioned to transform treatment paradigms and enhance the quality of care for patients and healthcare providers alike.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?